Since the onset of ovarian cancer tends to occur later in carriers of a BRCA2 variant, RRSO for managing ovarian cancer risk in these women is recommended between the ages of 40 and 45, unless the age at diagnosis in the family warrants considering this prophylactic surgery at an earlier age. This evidence concerns the gene BRCA2 and ovarian cancer.